Chance Pharmaceuticals, a Hangzhou, China-based clinical-stage biotechnology company, raised $30M in Series C financing.
The round was led by Lapam Capital with participation from CMS Capital and HEDA BioVenture and existing investor Guozhong Capital.
The company intends to use the funds to advance its research and development efforts for its innovative pipeline of inhalation therapies, initiate additional business collaborations, and accelerate the construction of a manufacturing facility.
Led by Dr. Donghao Chen, founder and CEO, Chance Pharmaceuticals provides, discover, develops, and commercializes inhalation therapies for the world’s debilitating diseases such as chronic obstructive pulmonary disease, asthma, pulmonary arterial hypertension, and central nervous system disorders.
FinSMEs
12/10/2021